Puma Biotechnology, Inc. (PBYI)

Puma Biotechnology's stock has increased by 76.09% in the past six months. Key events include Q1 2025 net income of $3 million and revenue of $46.0 million, Q2 2025 revenue of $52.4 million and net income of $5.9 million, analyst rating changes from Weiss Ratings and Wall Street Zen, an upcoming Q3 2025 financial results conference call, and positive momentum around its pipeline, particularly alisertib.

Puma Biotechnology's product sales exhibit some seasonality. The first quarter (Q1) is traditionally the lowest revenue quarter for the company, primarily due to inventory drawdowns at specialty pharmacies and distributors following the holiday periods.

Puma Biotechnology, Inc. is a biopharmaceutical company focused on developing and commercializing cancer treatments. Its main product is NERLYNX (neratinib), an oral medication for HER2-overexpressed/amplified breast cancer and advanced or metastatic HER2-positive breast cancer. The company is also developing alisertib for various cancers.

Puma Biotechnology operates in the United States and internationally. NERLYNX is marketed in the United States and has European Commission authorization. The company has expanded globally through licensing agreements with companies like Pierre Fabre, CANbridge Life Sciences, Medison Pharma, Knight Therapeutics, Specialised Therapeutics, and Pint Pharma.

Specific events impacting Puma Biotechnology's brand reputation in the past year were not prominently featured in the search results. The available information primarily focuses on financial performance, product development, clinical trial updates, and stock analyst ratings.

Puma Biotechnology has a mixed ownership structure: 25.89% institutional, 16.12% insiders, and 57.99% public companies and individual investors. Major institutional owners include Acorn Capital Advisors, Llc, BlackRock, Inc., and Vanguard Group Inc. Alan Auerbach, the company's founder, is the largest individual shareholder.